E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?

Detalles Bibliográficos
Autor principal: Zhang, Liyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058311/
https://www.ncbi.nlm.nih.gov/pubmed/35352486
http://dx.doi.org/10.1111/1759-7714.14399
_version_ 1784698085896617984
author Zhang, Liyi
author_facet Zhang, Liyi
author_sort Zhang, Liyi
collection PubMed
description
format Online
Article
Text
id pubmed-9058311
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-90583112022-05-03 E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell? Zhang, Liyi Thorac Cancer Editorial John Wiley & Sons Australia, Ltd 2022-03-29 2022-05 /pmc/articles/PMC9058311/ /pubmed/35352486 http://dx.doi.org/10.1111/1759-7714.14399 Text en © 2022 The Author. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Zhang, Liyi
E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title_full E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title_fullStr E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title_full_unstemmed E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title_short E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
title_sort e2112—does a negative phase iii trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058311/
https://www.ncbi.nlm.nih.gov/pubmed/35352486
http://dx.doi.org/10.1111/1759-7714.14399
work_keys_str_mv AT zhangliyi e2112doesanegativephaseiiitrialofendocrinetherapyplushistonedeacetylaseinhibitorinhormonereceptorpositiveadvancedbreastcancerrepresentadeathknell

Ejemplares similares